NCI-H3122Homo sapiens (Human)Cancer cell line
Also known as: NCIH3122, H-3122, H3122
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_5160 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Male |
Disease Information
| Disease | Lung adenocarcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Lung Adenocarcinoma |
| OncoTree Code | LUAD |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-000337_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene fusion | ALK | EML4-ALK | - | E6A20 v3 fusion | PubMed=35933914, PubMed=31882684 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Comparative proteome analysis across non-small cell lung cancer cell lines.
Daub H.
J. Proteomics 130:1-10(2016).
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Engelman J.A.
Cancer Discov. 4:662-673(2014).
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
Chung D.H., Heo D.S.
J. Thorac. Oncol. 8:415-422(2013).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).
Lung cancer cell lines as tools for biomedical discovery and research.
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
J. Natl. Cancer Inst. 102:1310-1321(2010).
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Janne P.A.
Clin. Cancer Res. 14:4275-4283(2008).
Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of paclitaxel.
Breathnach O.S., Johnson B.E.
Oncology 64:399-406(2003).
Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.
Oncogene 19:4632-4639(2000).
Loss of spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors.
Workman P.
bioRxiv 2022:06.08.495301-06.08.495301(2022).